Detection of serum and cellular AFP and hCG has made a significant contribution in understanding and management of testicular cancer. It is essential to remember the following events in utilizing these markers: (1) Histologic diagnosis of seminoma, but AFP is elevated. There is usually an element of choriocarcinoma. (2) Histologic diagnosis of seminoma and highly elevated hCG greater than 100 ng/ml has usually an element of choriocarcinoma. (3) Histologic diagnosis of choriocarcinoma with an elevated serum AFP. There is usually an element of embryonal carcinoma. (4) Pathologic stage I nonseminomatous testicular cancer with elevated serum markers is either stage II or stage III. (5) In a recent study of 23 patients undergoing resection of residual nonseminomatous testicular cancer after intensive chemotherapy, 21 had either teratoma in primary tumor or bulky metastatic disease. The markers were normalized after chemotherapy and prior to resection. (6) Although normalization of these markers after chemotherapy indicates effective therapeutic response, one should look of residual tumor utilizing radiologic investigations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000474885 | DOI Listing |
BJUI Compass
January 2025
Department of Urology Guy's & St. Thomas' Hospital, and Faculty of Life Sciences & Medicine, King's College London London UK.
Objectives: This study aimed to assess current international clinician practices, attitudes and barriers related to testicular prosthesis implantation in patients with testicular cancer at the time of radical inguinal orchidectomy.
Methods: An international online survey of urologists who perform radical orchidectomy for testicular cancer was developed. The recruitment process used social media and the emailing lists of national urological societies.
Even though Leydig cell tumor (LCT) represents the most common neoplasia among testicular sex cord-stromal tumors (SCSTs), it is a rare condition, comprising 1-2% of all testicular tumors, with a 10% risk of malignancy most commonly located in retroperitoneal lymph nodes. LCTs may demonstrate various clinical manifestations - from asymptomatic intratesticular swelling through nonspecific symptoms such as loss of libido, impotence or infertility, up to feminizing or virilizing syndromes due to hormonal activity of the tumor. This article presents a case of Leydig cell tumor that was associated with azoospermia what have rarely been reported worldwide.
View Article and Find Full Text PDFEur J Pharmacol
January 2025
Department of Physiology, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
Carvacrol is a common ingredient in the pharmaceutical, cosmetic, and perfume industries. It possesses various pharmaceutical properties including pain relief, anti-cell death, antioxidant, anti-cancer, and anti-inflammatory effects. We investigated the protective impact of carvacrol on infertility caused by varicocele in rats.
View Article and Find Full Text PDFUrol Case Rep
January 2025
Faculty member, Faculty of Medicine, Pathology Department, Damascus University, Damascus, Syrian Arab Republic.
Leydig cell tumors (LCTs) are rare testicular neoplasms, representing 1-3% of all testicular tumors. A 65-year-old male presented with a painless left scrotal mass. Ultrasound revealed a 61 × 53 × 35 mm tumor with heterogeneous echogenicity and abundant blood supply.
View Article and Find Full Text PDFUrology
January 2025
Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address:
This review examines the historical evolution of testicular cancer (TCa) treatment, emphasizing the transformative impact of World War II. Prior to the war, cases of more than 50 testicular tumors were exceedingly rare. The mobilization of American troops, especially after the German Blitz, resulted in widespread military health screenings, leading to a surge in incidental TCa diagnoses during the 1940s.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!